Other languages BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Market Closed - Nasdaq Other stock markets 03:59:48 2024-06-04 pm EDT			5-day change	1st Jan Change
1.62 ^USD	-4.14%		-12.90%	-45.08%

May. 09	BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 09	Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	Apr. 22
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia	Apr. 10
BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants	Mar. 25
50 valores para invertir en IA, salud, movilidad y energía	Mar. 25
50 aandelen om te beleggen in KI, gezondheid, mobiliteit en energie	Mar. 23
50 titoli per investire in AI, salute, mobilità ed energia	Mar. 22
50 Top-Aktien für Investitionen in KI, Gesundheit, Mobilität und Energie	Mar. 22
50 valeurs pour investir dans l'IA, la Santé, la Mobilité et l'Energie	Mar. 22
BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia	Mar. 15
BioXcel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 12
BioXcel Therapeutics Shares Soar After Terminating Proposed $60 Million Stock Offering	Feb. 13
BioXcel Therapeutics' BXCL701 Granted FDA Fast-Track Designation to Treat Small Cell Neuroendocrine Prostrate Cancer	Feb. 12
BioXcel Therapeutics, Inc. Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer	Feb. 12
Top Midday Decliners	Feb. 09
BioXcel Therapeutics Starts $60 Million Public Offering; Shares Drop	Feb. 09
Wall Street Set to Open Modestly Higher as S&P Hovers Just Above 5,000	Feb. 09
Positive Quarterly Earnings Boost Exchange-Traded Funds, Equity Futures Pre-Bell Friday	Feb. 09
US Futures Nudge Higher as S&P Remains Just Above 5,000	Feb. 09
Top Premarket Decliners	Feb. 09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Other languages

Filters